Compare Dyne Therapeutics Inc. Common Stock (DYN) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs UnitedHealth Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while UnitedHealth Group Inc trades at $395.65 (market cap $339.08B). The key difference: UnitedHealth Group Inc is far larger — about 118.6× Dyne Therapeutics Inc. Common Stock's market cap, and UnitedHealth Group Inc pays a 2.46% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| DYN | UNH | |
|---|---|---|
Market Cap | $2.86B | $339.08B |
Volume | 3,341,579 | 12,648,635 |
Sector | Health | Health |
52-Week High | $26.78 | $436.35 |
52-Week Low | $14.60 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $2.18B | $380.94B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
UnitedHealth Group (UNH) trades at $378.52, down 0.21% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats in recent quarters, including Q3 2026 EPS of $4.69 beating expectations of $4.14. Revenue growth remains solid at $447.57B for 2025, though net margins have compressed to 3.14%. Recent developments include strategic moves with TPG for WellMed operations and continued AI investments in Optum Insight.
UNH presents a compelling investment case with 82.7% analyst buy ratings and a $470.11 consensus price target representing 24% upside. The company's Medicare Advantage strength and Optum improvements support growth, though regulatory scrutiny and medical cost pressures remain key risks. Strong institutional ownership and Michael Burry's recent call option position signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
